[go: up one dir, main page]

MX2011007267A - Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina. - Google Patents

Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.

Info

Publication number
MX2011007267A
MX2011007267A MX2011007267A MX2011007267A MX2011007267A MX 2011007267 A MX2011007267 A MX 2011007267A MX 2011007267 A MX2011007267 A MX 2011007267A MX 2011007267 A MX2011007267 A MX 2011007267A MX 2011007267 A MX2011007267 A MX 2011007267A
Authority
MX
Mexico
Prior art keywords
oxo
pharmaceutical compositions
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
MX2011007267A
Other languages
English (en)
Inventor
Domenico Fanara
Monique Berwaer
Serge Cuypers
Valery Barillaro
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MX2011007267A publication Critical patent/MX2011007267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una formulación de liberación inmediata de los compuestos farmacéuticos.
MX2011007267A 2009-01-29 2010-01-27 Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina. MX2011007267A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09100083 2009-01-29
PCT/EP2010/050892 WO2010094535A1 (en) 2009-01-29 2010-01-27 Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
MX2011007267A true MX2011007267A (es) 2011-08-15

Family

ID=40622206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007267A MX2011007267A (es) 2009-01-29 2010-01-27 Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.

Country Status (22)

Country Link
US (2) US20120108464A1 (es)
EP (1) EP2391349B1 (es)
JP (1) JP5576401B2 (es)
KR (1) KR101640164B1 (es)
CN (2) CN104083328B (es)
AU (1) AU2010215646B2 (es)
BR (1) BRPI1007161B1 (es)
CA (1) CA2747395C (es)
CY (1) CY1115673T1 (es)
DK (1) DK2391349T3 (es)
EA (1) EA022057B1 (es)
ES (1) ES2511047T3 (es)
HR (1) HRP20141006T1 (es)
IL (1) IL213545A (es)
ME (1) ME01927B (es)
MX (1) MX2011007267A (es)
PL (1) PL2391349T3 (es)
PT (1) PT2391349E (es)
RS (1) RS53554B1 (es)
SI (1) SI2391349T1 (es)
SM (1) SMT201400155B (es)
WO (1) WO2010094535A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275693A1 (en) * 2009-01-29 2011-11-10 Ucb Pharma, S.A. Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives
CN104800176A (zh) * 2015-04-23 2015-07-29 广东赛烽医药科技有限公司 一种布瓦西坦口崩片及其制备方法
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
MX2020001877A (es) 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
TW201912157A (zh) * 2017-08-18 2019-04-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群及子宮腺肌症之固體醫藥調配物
CN109833300A (zh) * 2017-11-28 2019-06-04 浙江京新药业股份有限公司 一种抗癫痫药物口服组合物及其制备方法
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
CN113288872A (zh) * 2020-02-21 2021-08-24 广东东阳光药业有限公司 一种2-吡咯烷酮衍生物的组合物及其制备方法
CN112933059A (zh) * 2021-03-25 2021-06-11 浙江昂利康制药股份有限公司 一种布立西坦片剂的干法制粒工艺
CN115192572B (zh) * 2021-04-08 2023-09-19 成都同道慧宜生物医药科技有限公司 布立西坦药剂、其制备方法和应用
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
EP4431086A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
EP4491177A1 (en) 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. Film coated tablets of brivaracetam
EP4491176A1 (en) 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet comprising brivaracetam
EP4527378A1 (en) 2023-09-22 2025-03-26 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet of brivaracetam

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
JP2005298338A (ja) 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
CN1186094C (zh) * 2002-07-01 2005-01-26 蔡海德 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法
WO2006099005A1 (en) * 2005-03-09 2006-09-21 Trustees Of Dartmouth College Method for identifying agents which modulate gtpase activity involved in insulin-stimulated glut4 translocation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
SI1909764T1 (sl) * 2005-07-26 2015-01-30 Ucb Pharma, S.A. Farmacevtski sestavki, ki obsegajo levetiracetam in postopek za njihovo pripravo
CN101506157B (zh) * 2006-06-08 2013-07-24 Ucb医药有限公司 吡咯烷酮共结晶
KR101468053B1 (ko) * 2006-08-31 2014-12-02 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템
US20080280862A1 (en) * 2007-01-05 2008-11-13 Cermak Jennifer M Methods, compositions, and kits for the treatment of pain
US20110275693A1 (en) * 2009-01-29 2011-11-10 Ucb Pharma, S.A. Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives

Also Published As

Publication number Publication date
SI2391349T1 (sl) 2014-12-31
CN104083328B (zh) 2017-04-12
WO2010094535A1 (en) 2010-08-26
AU2010215646B2 (en) 2014-03-27
RS53554B1 (sr) 2015-02-27
JP2012516302A (ja) 2012-07-19
KR101640164B1 (ko) 2016-07-15
EP2391349B1 (en) 2014-07-23
PL2391349T3 (pl) 2014-12-31
CA2747395C (en) 2015-01-13
ES2511047T3 (es) 2014-10-22
HK1198287A1 (en) 2015-03-27
BRPI1007161A2 (pt) 2016-02-23
CN102292071B (zh) 2016-08-24
BRPI1007161B1 (pt) 2022-03-22
US20120108464A1 (en) 2012-05-03
SMT201400155B (it) 2015-01-15
EA022057B1 (ru) 2015-10-30
IL213545A0 (en) 2011-07-31
CN102292071A (zh) 2011-12-21
KR20120008022A (ko) 2012-01-25
EA201101116A1 (ru) 2012-03-30
EP2391349A1 (en) 2011-12-07
AU2010215646A1 (en) 2011-08-04
CY1115673T1 (el) 2017-01-25
HK1161988A1 (zh) 2012-08-17
US10729653B2 (en) 2020-08-04
IL213545A (en) 2016-05-31
ME01927B (me) 2015-05-20
US20110281929A1 (en) 2011-11-17
CN104083328A (zh) 2014-10-08
JP5576401B2 (ja) 2014-08-20
PT2391349E (pt) 2014-10-27
HRP20141006T1 (hr) 2014-12-19
CA2747395A1 (en) 2010-08-26
DK2391349T3 (da) 2014-11-03

Similar Documents

Publication Publication Date Title
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
JOP20180102A1 (ar) مركب صيدلاني
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
LT2373681T (lt) Albiglutido farmacinės kompozicijos
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IN2012DN02793A (es)
IL219369A0 (en) Solid pharmaceutical compositions containing an integrase inhibitor
TN2009000510A1 (en) Extended release formulation of nevirapine
WO2010049449A3 (en) Novel salts of sunitinib
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
MX339361B (es) Derivados de alternano.
IL210279A0 (en) Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
WO2011045774A3 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
EP2568810A4 (en) COMPOSITIONS OF DARUNAVIR
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
PT2429501T (pt) Composições de libertação imediata de fármaco
IN2013MU03317A (es)
PL2277511T3 (pl) Kompozycje farmaceutyczne lewetiracetamu o przedłużonym uwalnianiu
HK1178078B (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
HK1178078A (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs

Legal Events

Date Code Title Description
FG Grant or registration